what is the primary effect of gastric inhibitory peptide stimulation of glucose-dependent insulin secretion - What is the primary effect ofgastric-inhibitorypeptidequizlet promotes insulin secretion Unraveling the Primary Effect of Gastric Inhibitory Peptide (GIP)

Gastric inhibitorypolypeptide supplement Gastric Inhibitory Peptide (GIP), also known as Glucose-dependent insulinotropic polypeptide, is a fascinating gastrointestinal hormone playing a crucial role in nutrient metabolism and glucose homeostasisGastric Inhibitory Polypeptide (human) (hGIP), [ 125 I], 10 µCi. While its name suggests a primary role in inhibiting gastric secretions, extensive research has illuminated its multifaceted effects, with its most significant primary effect being the stimulation of glucose-dependent insulin secretion. This action is vital in preventing postprandial hyperglycemia, ensuring that the body efficiently manages the influx of glucose after a meal.

First discovered for its ability to influence gastric acid secretion, GIP was initially designated as gastric inhibitory polypeptideThe primary effect of gastric-inhibitory peptide (GIP) isto act as an incretin to lower blood glucose levels. It is also known by the name glucose-dependent .... However, modern understanding, supported by numerous studies, reveals that while it has a modest inhibitory effect on gastric acid secretion, this is secondary to its potent insulinotropic actionGIPlevels rise immediately after nutrient ingestion, leading to modest inhibitoryeffectson gastric acid secretion and gastrointestinal motility. The .... This hormone is secreted by K cells located in the duodenum and intestine in response to the ingestion of nutrients, particularly carbohydrates and fats. The "glucose-dependent" aspect of its other name, Glucose-dependent insulinotropic polypeptide, is key; its ability to stimulate insulin secretion is amplified when blood glucose levels are elevated.Gastric Inhibitory Polypeptide (GIP) is defined as a 42-amino-acid gastrointestinal hormone thatmediates insulin secretion in response to nutrient intake, ...

The incretin effect, a phenomenon where oral glucose elicits a higher insulin response than intravenous glucose, is largely mediated by GIP and its counterpart, Glucagon-like peptide-1 (GLP-1). GIP amplifies glucose-dependent insulin secretion from the pancreatic beta cells in the pancreas2024年7月9日—The role of GIP in fat metabolism is equally compelling. Itpromotes glucose uptake by fat cellsand stimulates the activity of fatty acid .... This means that as glucose levels rise after a meal, GIP signals the beta cells to release insulin, effectively lowering blood glucose levels. This mechanism is fundamental to maintaining normal blood sugar levels and preventing the detrimental consequences of hyperglycemia.What Is Gastric Inhibitory Peptide and Why Is It Important?

Beyond its primary role in insulin release, GIP has several other important functions.作者：Y Yamada·2006·被引用次数：78—GIP was originally isolated for its ability to influencegastric acid secretionand was designated as gastric inhibitory polypeptide (43). It contributes to the promotion of growth and survival of the pancreatic beta-cell, ensuring a healthy insulin-producing capacity2024年7月9日—The role of GIP in fat metabolism is equally compelling. Itpromotes glucose uptake by fat cellsand stimulates the activity of fatty acid .... Furthermore, GIP promotes glucose uptake by fat cells and stimulates the activity of fatty acid synthesis, playing a role in energy storage and utilization.GIP and GLP‐1, the two incretin hormones - PubMed Central Research also indicates GIP's involvement in regulating skeletal homeostasis and potentially influencing adipogenesis.

Historically, GIP was thought to strongly inhibit gastric motility and acid secretion. While it does exert some inhibitory effects on gastric motility, its effect on gastric acid secretion is now understood to be weaker and more context-dependent, especially compared to its robust stimulatory effect on insulin secretion. In some animal models, GIP was shown to inhibit acid secretion, but its role in human gastric physiology is nuanced.

Interestingly, the effect of GIP is not solely limited to insulin. Under certain conditions, particularly at lower glucose concentrations, GIP has been shown to stimulate glucagon secretion.Gastric inhibitory polypeptide (GIP) dose-dependently ... However, at higher glucose levels, its effect on glucagon becomes more complex, with studies indicating that GIP can counteract the suppression of glucagon secretion by glucose. This intricate interplay highlights the sophisticated regulation of glucose metabolismThe primary action of GIP is thestimulation of glucose-dependent insulin secretion. GIP may also play a role in adipocyte biology. Cas No, 100040-31-1..

The understanding of GIP's function has significant implications for the management of metabolic disorders like diabetes and obesity. Its role in enhancing insulin secretion after eating makes it a critical component in preventing postprandial hyperglycemia作者：JJ Meier·2004·被引用次数：206—The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been demonstratedto inhibit gastric acid secretionand was proposed to possess .... While GLP-1 is known for its appetite-suppressing effects leading to weight loss, GIP's role in obesity is more complex and might involve regulation of energy intake and expenditure. Research into inhibiting endogenous GIP or its receptor in an obesity setting has shown potential for decreased energy intake, increased energy expenditure, or a combination of both, suggesting a potential therapeutic avenue for weight loss.What is the role of Gastric Inhibitory Polypeptide (GIP) and ...

In summary, while GIP was initially identified for its inhibitory influence on gastric functions, its primary effect is undeniably its potent ability to stimulate insulin secretion in a glucose-dependent manner. This crucial incretin function, alongside its other metabolic roles, underscores the importance of GIP in maintaining overall metabolic health and provides a focal point for ongoing research into treatments for metabolic diseases.